Variability of definition of high‐risk multiple myeloma across phase III clinical trials

The definition of high‐risk multiple myeloma (HRMM) is evolving. Use of a clear definition of HRMM in clinical trials was not previously studied. We explored the definition of HRMM in completed phase III clinical trials. There is extreme variability in the definition and cutoffs used to define HRMM,...

Full description

Saved in:
Bibliographic Details
Published inEJHaem Vol. 4; no. 2; pp. 454 - 458
Main Authors Abu Za'nouneh, Faris Jamal, Ababneh, Obada, Schinke, Carolina, Thanendrarajan, Sharmilan, Zangari, Maurizio, Shaughnessy, John D., Zhan, Fenghuang, Rhee, Frits, Al Hadidi, Samer
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.05.2023
John Wiley and Sons Inc
Wiley
Subjects
Clinical trials
Cytogenetics
Dehydrogenases
Funding
Gene expression
high risk
Medical prognosis
Multiple myeloma
Patients
phase III
Plasma
Regression analysis
Short Report
Short Reports
United States > US
multiple myeloma
clinical trials
high risk
phase III
Online AccessGet full text

Cover

More Information
Summary:The definition of high‐risk multiple myeloma (HRMM) is evolving. Use of a clear definition of HRMM in clinical trials was not previously studied. We explored the definition of HRMM in completed phase III clinical trials. There is extreme variability in the definition and cutoffs used to define HRMM, with a significant number of studies lacking a clear definition. Our study provides a quantification of the variability in defining HRMM and suggests a need to better define HRMM in future clinical trials to enable more consistent treatment recommendations.
Bibliography:Faris Jamal Abu Za'nouneh and Obada Ababneh co‐first authors, contributed equally.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2688-6146
2688-6146
DOI:10.1002/jha2.675